Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J. 1992; 11: 3887-3895
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J Exp Med. 1995; 182: 459-465
- The future of immune checkpoint therapy.Science. 2015; 348: 56-61
- Enhancement of antitumor immunity by CTLA-4 blockade.Science. 1996; 271: 1734-1736
- Ipilimumab: first global approval.Drugs. 2011; 71: 1093-1104
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.J Immunother Cancer. 2019; 7: 278
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med. 2015; 372: 2006-2017
- Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.Cancers. 2020; 12: 738
- Cancer immunotherapy using checkpoint blockade.Science. 2018; 359: 1350-1355
- Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.Cancer Res. 2012; 72: 917-927
- LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.Cancer Res. 2014; 74: 3418-3428
- LBA18 - efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations.Ann Oncol. 2017; 28: v611-v612
- The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy.Genes Cancer. 2018; 9: 176-189
- Tim-3 finds its place in the cancer immunotherapy landscape.J Immunother Cancer. 2020; 8: e000911
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.J Exp Med. 2010; 207: 2175-2186
- TIM-3 in leukemia; immune response and beyond.Front Oncol. 2021; 11: 753677
- TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.PLoS One. 2012; 7: e30676
- Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.Cancer Res. 2011; 71: 3540-3551
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.J Exp Med. 2010; 207: 2187-2194
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.Blood. 2011; 117: 4501-4510
- Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.J Hematol Oncol. 2020;
- Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.Oncotarget. 2018; 9: 8706-8715
- Immune checkpoint inhibitors side effects and management.Immunotherapy. 2016; 8: 799-807
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med. 2012; 366: 2455-2465
- Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis.Clin Lung Cancer. 2018; 19: e335-e348
- Prognostic and predictive markers for the new immunotherapies.Oncology (Williston Park). 2014; 28: 39-48
- Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med. 2015; 372: 320-330
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2015; 16: 375-384
- Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med. 2015; 373: 123-135
- Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med. 2015; 372: 2018-2028
- The cancer immunotherapy biomarker testing landscape.Arch Pathol Lab Med. 2020; 144: 706-724
- Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer.JAMA Oncol. 2016; 2: 46-54
- A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer.JAMA Oncol. 2017; 3: 1051-1058
- Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response.Lung Cancer. 2019; 134: 79-84
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.Ann Oncol. 2016; 27: 147-153
- Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma.Clin Lung Cancer. 2018; 19: e421-e430
- PD-L1 assays 22C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs: an interclone evaluation by differently trained pathologists.Am J Surg Pathol. 2018; 42: 1384-1389
- PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.Oncotarget. 2018; 9: 30465-30471
- DNA mismatch repair: functions and mechanisms.Chem Rev. 2006; 106: 302-323
- Mismatch repair in replication fidelity, genetic recombination, and cancer biology.Annu Rev Biochem. 1996; 65: 101-133
- Mismatch repair deficiency testing in clinical practice.Expert Rev Mol Diagn. 2016; 16: 591-604
- Mutations associated with HNPCC predisposition — update of ICG-HNPCC/INSiGHT mutation database.Dis Markers. 2004; 20: 269-276
- Milestones of Lynch syndrome: 1895-2015.Nat Rev Cancer. 2015; 15: 181-194
- Landscape of microsatellite instability across 39 cancer types.JCO Precis Oncol. 2017; 2017 (PO.17.00073)
- Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.Nat Genet. 2020; 52: 331-341
- Direct mutational analysis in a family with hereditary non-polyposis colorectal cancer.Aust N Z J Med. 1994; 24: 682-686
- Microsatellites: simple sequences with complex evolution.Nat Rev Genet. 2004; 5: 435-445
- Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.Carcinogenesis. 2008; 29: 673-680
- Microsatellites within genes: structure, function, and evolution.Mol Biol Evol. 2004; 21: 991-1007
- Making sense of missense in Lynch syndrome: the clinical perspective.Cancer Prev Res (Phila). 2010; 3: 1371-1374
- A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.Cancer Res. 1998; : 5248-5257
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science. 2017; 357: 409-413
- Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers.JAMA Oncol. 2018; 4: 157-158
- Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.N Engl J Med. 2020; 383: 2207-2218
- ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis).Genet Med. 2014; 16: 101-116
- Relevance, pathogenesis, and testing algorithm for mismatch repair–defective colorectal carcinomas.J Mol Diagn. 2012; 14: 91-103
- Applicability of next generation sequencing technology in microsatellite instability testing.Genes. 2015; 6: 46-59
- Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS.Oncotarget. 2017; 8: 7452-7463
- Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing.J Mol Diagn. 2017; 19: 84-91
- Microsatellite instability detection by next generation sequencing.Clin Chem. 2014; 60: 1192-1199
- Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.Cancer Med. 2018; 7: 746-756
- Classification and characterization of microsatellite instability across 18 cancer types.Nat Med. 2016; 22: 1342-1350
- Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data.JCO Precis Oncol. 2017;
- Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels.J Clin Oncol. 2016; 34: 2141-2147
- Signatures of mutational processes in human cancer.Nature. 2013; 500: 415-421
- The repertoire of mutational signatures in human cancer.Nature. 2020; : 1-28
- Genetic basis for clinical response to CTLA-4 blockade in melanoma.N Engl J Med. 2014; 371: 2189-2199
- Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.N Engl J Med. 2018; 378: 2093-2104
- Genomic features of response to combination immunotherapy in patients with advanced non- small-cell lung cancer.Cancer Cell. 2018; 33: 843-852.e844
- Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science. 2015; 348: 124-128
- Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.Mol Cancer Ther. 2017; 16: 2598-2608
- Tumor mutational burden and response rate to PD-1 inhibition.N Engl J Med. 2017; 377: 2500-2501
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365
- The spectrum of benefit from checkpoint blockade in hypermutated tumors.N Engl J Med. 2021; 384: 1168-1170
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med. 2017; 19: 94
- DNA damage and repair biomarkers of immunotherapy response.Cancer Discov. 2017; 7: 675-693
- Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing.J Clin Oncol. 2018; 36: 633-641
- Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.Oncotarget. 2015; 6: 34221-34227
- Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database.JAMA. 2019; 321: 1391-1399
- Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer.Clin Cancer Res. 2019; 25: 5015-5026
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet. 2017; 389: 67-76
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Nat Med. 2018; 24: 1441-1448
- Targeted next generation sequencing identifies markers of response to PD-1 blockade.Cancer Immunol Res. 2016; 4: 959-967
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types.Nat Genet. 2019; 51: 202-206
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science. 2016; 351: 1463-1469
- Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.J Clin Oncol. 2011; 29: 1949-1955
- Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.J Clin Oncol. 2011; 29: 610-618
- Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade.Cancer Discov. 2016; 6: 827-837
- Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open- label, multicohort KEYNOTE-173 study.Ann Oncol. 2020; 31: 569-581
- PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature. 2014; 515: 568-571
- Multispectral fluorescence imaging allows for distinctive topographic assessment and subclassification of tumor-infiltrating and surrounding immune cells.Methods Mol Biol. 2019; 1913: 13-31
- Multiplexed immunohistochemistry for molecular and immune profiling in lung cancer-just about ready for prime-time?.Cancers. 2019; 12: 283
- State-of-the-Art of profiling immune contexture in the era of multiplexed staining and digital analysis to study paraffin tumor tissues.Cancers. 2019; 12: 247
- Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.J Immunother Cancer. 2018; 6: 99
- Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/Ido-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma.Clin Cancer Res. 2018; 24: 5250-5260
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.Science. 2018; 362: eaar3593
- T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028.J Clin Oncol. 2019; 37: 318-327
- HLA-binding properties of tumor neoepitopes in humans.Cancer Immunol Res. 2014; 2: 522-529
- Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers.Cancer Discov. 2019; 9: 1022-1035
- Neoantigens in cancer immunotherapy.Science. 2015; 348: 69-74
- “Final common pathway” of human cancer immunotherapy: targeting random somatic mutations.Nat Immunol. 2017; 18: 255-262
- High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.Cancer Res. 2010; 70: 9073-9083
- High sensitivity of cancer exome-based CD8 T cell neo-antigen identification.Oncoimmunology. 2014; 3: e28836
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science. 2018; 359: 91-97
- The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.Science. 2018; 359: 104-108
- Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science. 2018; 359: 97-103
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Science. 2018; 359: 582-587
- Allele-specific HLA loss and immune escape in lung cancer evolution.Cell. 2017; 171: 1259-1271.e11
- The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.Nat Rev Cancer. 2019; 19: 133-150
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.Ann Oncol. 2019; 30: 1232-1243
- Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Nat Biotechnol. 2022; 40: 499-506
Article info
Publication history
Published online: August 22, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
